<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03650920</url>
  </required_header>
  <id_info>
    <org_study_id>5180105</org_study_id>
    <nct_id>NCT03650920</nct_id>
  </id_info>
  <brief_title>Hepatitis C Virus (HCV) Positive Liver Grafts in HCV Negative Recipients</brief_title>
  <official_title>Pilot Investigation Using HCV Positive Liver Grafts in HCV Negative or Previously Successfully Treated Recipients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Loma Linda University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Loma Linda University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To provide proof-of-concept data on the efficacy/safety of transplanting HCV positive donor
      grafts in HCV sero-negative liver recipients who are currently listed.
    </textblock>
  </brief_summary>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">September 2, 2018</start_date>
  <completion_date type="Anticipated">September 2021</completion_date>
  <primary_completion_date type="Anticipated">September 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Patient survival rate</measure>
    <time_frame>From the date of transplant through the last day of 15 month post transplant</time_frame>
    <description>Will track all subjects post transplant for 15 months</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Liver Failure</condition>
  <arm_group>
    <arm_group_label>Recipient of HCV positive liver graft</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A single center, open-label, pilot study examining 10 adult HCV negative liver transplant subjects who receive an HCV infected graft. Target start date for antiviral therapy will be within 3 months after liver transplantation, unless extenuating clinical circumstances arise (such as fibrosing cholestatic HCV, which would prompt earlier treatment, or non-hepatic comorbidities which would prompt delay in treatment).</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Liver Transplantation</intervention_name>
    <description>A HCV negative or previously successfully treated recipient with a HCV positive liver graft</description>
    <arm_group_label>Recipient of HCV positive liver graft</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female

          -  Age 18 and older

          -  Active on the transplant list

          -  Donor organ with Antibody and nucleic acid test (NAT) positive for HCV

          -  Graft with F2 fibrosis or less at time of explant

          -  HCV negative recipient; this includes patients who never had HCV and those with HCV
             previously eradicated with antiviral therapy. The latter is defined as those with
             undetectable HCV viral load at least 3 months since stopping therapy.

          -  Willing and able to provide written informed consent or for those subjects where
             hepatic encephalopathy affects their ability to provide initial or ongoing consent,
             has an appropriate and legally-authorized representative willing and able to provide
             consent on behalf of the subject

        Exclusion Criteria:

          -  Participants co-infected with HIV

          -  Donor previously treated with a non-structural protein 5A (NS5a) containing regimen
             (if treatment history of donor known)

          -  Known allergies or hypersensitivity to direct acting antiviral drug (DAA) or ribavirin
             (RBV)

          -  Pregnancy and/or actively breastfeeding
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael L Volk, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Loma Linda</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Loma Linda University Transplant Institute</name>
      <address>
        <city>Loma Linda</city>
        <state>California</state>
        <zip>92354</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.ncbi.nlm.nih.gov/pubmed/28556422</url>
    <description>Related Info</description>
  </link>
  <reference>
    <citation>Levitsky J, Formica RN, Bloom RD, Charlton M, Curry M, Friedewald J, Friedman J, Goldberg D, Hall S, Ison M, Kaiser T, Klassen D, Klintmalm G, Kobashigawa J, Liapakis A, O'Conner K, Reese P, Stewart D, Terrault N, Theodoropoulos N, Trotter J, Verna E, Volk M. The American Society of Transplantation Consensus Conference on the Use of Hepatitis C Viremic Donors in Solid Organ Transplantation. Am J Transplant. 2017 Nov;17(11):2790-2802. doi: 10.1111/ajt.14381. Epub 2017 Jul 1.</citation>
    <PMID>28556422</PMID>
  </reference>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>August 27, 2018</study_first_submitted>
  <study_first_submitted_qc>August 27, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 29, 2018</study_first_posted>
  <last_update_submitted>February 20, 2020</last_update_submitted>
  <last_update_submitted_qc>February 20, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Loma Linda University</investigator_affiliation>
    <investigator_full_name>Michael Volk</investigator_full_name>
    <investigator_title>Medical Director of Liver Transplantation</investigator_title>
  </responsible_party>
  <keyword>HCV</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Failure</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

